


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound having the formula:



or a pharmaceutically acceptable salt or N-oxide thereof, wherein

the subscript n is 1;

the subscript m is an integer of from 0 to 2;

each R¹ is a substituent independently selected from the group consisting of -CO₂H, C₁₋₄ alkyl and C₁₋₄ haloalkyl, wherein the aliphatic portions of each of said R¹ substituents is optionally substituted with from one to three members selected from the group consisting of -OH, -OR^m, and -S(O)₂R^m wherein each R^m is independently an unsubstituted C₁₋₆ alkyl;

Ar¹ is phenyl, optionally substituted with from one to three R² substituents independently selected from the group consisting of halogen, -OR^c, -NR^cR^d, -SR^c, -R^e, -CN, -NO₂, -CO₂R^c, -CONR^cR^d, -C(O)R^c, -OC(O)NR^cR^d, -NR^dC(O)R^c, -NR^dC(O)₂R^e, -NR^c-C(O)NR^cR^d, -S(O)R^e, -S(O)₂R^e, -NR^cS(O)₂R^e, -S(O)₂NR^cR^d, -N₃, -X²OR^c, -O-X²OR^c, -X²NR^cR^d, -O-X²NR^cR^d, wherein X² is C₁₋₄ alkylene, and each R^c and R^d is independently selected from hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, and C₃₋₆ cycloalkyl, or optionally R^c and R^d when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 1 additional heteroatoms selected from N and O as ring members; and each R^e is independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, and C₃₋₆ cycloalkyl;

HAr is a heteroaryl group selected from the group consisting of pyrazolyl and benzopyrazolyl, each of which is linked through a ring member nitrogen atom to the remainder of the molecule and is substituted with from one to three R³ substituents independently selected from the group consisting of halogen, -OR^f, -NR^fR^g, -SR^f, -R^h, -CN, -NO₂, -CO₂R^f, -CONR^fR^g, -C(O)R^f, -X³OR^f, -X³OC(O)R^f, -X³NR^fR^g, -X³SR^f, -X³CN, -X³NO₂, -X³CO₂R^f, -X³CONR^fR^g, -X³C(O)R^f, -X³NR^gC(O)R^f, -X³NR^gC(O)₂R^h, -X³NR^f-C(O)NR^fR^g, -Y, -X³Y, and -X³N₃, wherein Y is selected from the group consisting of phenyl, thienyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl and oxadiazolyl, optionally substituted with from one to three substituents selected from the group consisting of halogen, -OR^f, and -R^h, and wherein each X³ is independently C₁₋₄ alkylene, and each R^f and R^g is independently selected from hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, and C₃₋₆ cycloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 1 additional heteroatoms selected from N and O as ring members, and each R^h is independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, and C₃₋₆ cycloalkyl,

L¹ is -CH₂- optionally substituted with a phenyl or C₁₋₈ alkyl; and with the proviso that the compound is other than CAS Reg. No. 492422-98-7, 1-[[4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-(5-chloro-2-methylphenyl)-piperazine; CAS Reg. No. 351986-92-0, 1-[[4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-(4-fluorophenyl)-piperazine; and CAS Reg. No. 356039-23-1, 1-[(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)acetyl]-4-(4-fluorophenyl)-piperazine; and **CAS Reg. No. 492992-15-1, 3-[3-Fluoro-4-[4-[(1-pyrazolyl)acetyl]piperazine-1-yl]phenyl]-5-[(isoxazol-3-yl)amino]methyl]isoxazole.**

2. (Canceled)
3. (Canceled)

4. (Previously Presented) A compound of claim 1, wherein Ar¹ is phenyl substituted with from 1 to 2 R² groups.
5. (Canceled)
6. (Previously Presented) A compound of claim 4, wherein HAr is pyrazolyl.
7. (Previously Presented) A compound of claim 6, wherein HAr is pyrazolyl which is substituted with three R³ groups and L¹ is -CH₂-.
8. (Canceled)
9. (Canceled)
10. (Previously Presented) A compound of claim 7, wherein one of said R³ groups is selected from the group consisting of -Y and -X³-Y, wherein Y is selected from the group consisting of phenyl, thienyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl and oxadiazolyl, which is optionally substituted with from one to three substituents independently selected from the group consisting of halogen, -OR^f, and -R^h, wherein each R^f is independently selected from the group consisting of H, C₁₋₈ alkyl, C₃₋₆ cycloalkyl and C₁₋₈ haloalkyl, and each R^h is independently selected from the group consisting of C₁₋₈ alkyl, C₃₋₆ cycloalkyl and C₁₋₈ haloalkyl.
11. (Previously Presented) A compound of claim 10, wherein Y is selected from the group consisting of phenyl and thienyl, each of which is optionally substituted with from one to three substituents independently selected from the group consisting of halogen, -OR^f, and -R^h, wherein each R^f is independently selected from the group consisting of H, C₁₋₈ alkyl, C₃₋₆ cycloalkyl and C₁₋₈ haloalkyl, and each R^h is independently selected from the group consisting of C₁₋₈ alkyl, C₃₋₆ cycloalkyl and C₁₋₈ haloalkyl.
12. (Canceled)

13. (Canceled)


14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Previously Presented) A compound of claim 1, having the formula:



wherein the subscript m is 0 or 1;

R¹ is C₁₋₄ alkyl, optionally substituted with -OH, -OR^m or -S(O)₂R^m;

R^{2a}, R^{2b}, R^{2c}, R^{2d} and R^{2e} are each members independently selected from the group consisting of hydrogen, halogen, -OR^c, -NR^cR^d, -SR^c, -R^e, -CN, -NO₂, -CO₂R^c, -CONR^cR^d, -C(O)R^c, -OC(O)NR^cR^d, -NR^dC(O)R^c, -NR^dC(O)R^e, -NR^c-C(O)NR^cR^d, -S(O)R^e, -S(O)₂R^e, -NR^cS(O)₂R^e, -S(O)₂NR^cR^d, -N₃, -X²OR^c, -O-X²OR^c, -X²NR^cR^d, -O-X²NR^cR^d, wherein X² is C₁₋₄ alkylene, and each R^c and R^d is independently selected from hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, and C₃₋₆ cycloalkyl, or optionally R^c and R^d when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 1 additional heteroatoms selected from N and O as ring members; and each R^e is independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, and C₃₋₆ cycloalkyl, such that at least two of R^{2a}, R^{2b}, R^{2c}, R^{2d} and R^{2e} are H;

R^{3a} , R^{3b} and R^{3c} are each members independently selected from the group consisting of hydrogen, halogen, $-OR^f$, $-NR^fR^g$, $-SR^f$, $-R^h$, $-CN$, $-NO_2$, $-CO_2R^f$, $-CONR^fR^g$, $-C(O)R^f$, $-X^3OR^f$, $-X^3OC(O)R^f$, $-X^3NR^fR^g$, $-X^3SR^f$, $-X^3CN$, $-X^3NO_2$, $-X^3CO_2R^f$, $-X^3CONR^fR^g$, $-X^3C(O)R^f$, $-X^3NR^gC(O)R^f$, $-X^3NR^gC(O)_2R^h$, $-X^3NR^f-C(O)NR^fR^g$, $-Y$, $-X^3Y$, and $-X^3N_3$, wherein Y is selected from the group consisting of phenyl, thienyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl and oxadiazolyl, optionally substituted with from one to three substitutents selected from the group consisting of halogen, $-OR^f$, and $-R^h$, and wherein each X^3 is independently C_{1-4} alkylene, and each R^f and R^g is independently selected from hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, and C_{3-6} cycloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 1 additional heteroatoms selected from N and O as ring members, and each R^h is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, and C_{3-6} cycloalkyl, such that at least one of R^{3a} , R^{3b} and R^{3c} is other than H.

19. (Original) A compound of claim 18, wherein at least one of R^{3a} , R^{3b} and R^{3c} is selected from the group consisting of $-Y$ and $-X^3-Y$.

20. (Original) A compound of claim 18, wherein m is 0 or 1; at least one of R^{2a} and R^{2e} is hydrogen.

21. (Original) A compound of claim 18, wherein R^{3b} is halogen.

22. (Canceled)

23. (Previously Presented) A compound of claim 20, wherein at least one of R^{3a} , R^{3b} and R^{3c} is selected from the group consisting of halogen, C_{1-4} alkyl and C_{1-4} haloalkyl.

24. (Previously Presented) A compound of claim 23, wherein R^{2d} is hydrogen and at least two of R^{3a}, R^{3b} and R^{3c} are selected from the group consisting of halogen, C₁₋₄ alkyl and C₁₋₄ haloalkyl.

25. (Original) A compound of claim 24, wherein R^{2c} is selected from the group consisting of F, Cl, Br, CN, NO₂, CO₂CH₃, C(O)CH₃ and S(O)₂CH₃, and each of R^{3a}, R^{3b} and R^{3c} is other than hydrogen.

26. (Previously Presented) A compound of claim 18, wherein R^{2a} and R^{2e} are each hydrogen.


27. (Previously Presented) A compound of claim 26, wherein at least one of R^{3a} , R^{3b} and R^{3c} is selected from the group consisting of halogen, C_{1-4} alkyl and C_{1-4} haloalkyl.

28. (Canceled)

29. (Canceled)

30. (Previously Presented) A compound of claim 18, wherein R^{2b} and R^{2e} are each hydrogen.

31. (Original) A compound of claim 18, having a formula selected from the group consisting of:



32. (Original) A compound of claim 31, wherein R^{3c} and R^{3a} are each independently selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl; and R^{3b} is halogen.

33. (Previously Presented) A compound of claim 31, wherein R^{3c} and R^{3a} are each independently selected from the group consisting of halogen, -NR^fR^g, -SR^f, -CO₂R^f, -Y and -R^h, wherein R^h is C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl.


34. (Original) A compound of claim 33, wherein R^{3b} is halogen.

35. (Original) A compound of claim 31, wherein m is 0.

36. (Canceled)


37. (Previously Presented) A compound of claim 31, wherein R^{2b} is selected from the group consisting of -SR^c, -O-X²-OR^c, -X²-OR^c, -R^e, -OR^c, -NR^cR^d, and -NR^cSO₂R^e.

38. (Original) A compound of claim 18, having the formula:




wherein R^{2c} is halogen, cyano or nitro; R^{2b} is selected from -SR^c, -O-X²-OR^c, -X²-OR^c, -R^e, -OR^c, -NR^cR^d, -NR^cS(O)₂R^e and -NR^dC(O)R^c; R^{3a} is selected from the group consisting of NH₂, CF₃, SCH₃ and Y; R^{3b} is chloro or bromo; and R^{3c} is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl.

39. (Original) A compound of claim 18, having the formula:



wherein R^{2c} is halogen, cyano or nitro; R^{2b} is selected from -SR^c, -O-X²-OR^c, -X²-OR^c, -R^e, -OR^c, -NR^cR^d, -NR^cS(O)₂R^e and -NR^dC(O)R^c; R^{3a} is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl; R^{3c} is selected from the group consisting of NH₂, CF₃, SCH₃ and Y; and R^{3b} is chloro or bromo.


40. (Previously Presented) A compound of claim 18, having the formula:



wherein R^{2c} is halogen, cyano or nitro; R^{2b} is selected from -SR^c, -O-X²-OR^c, -X²-OR^c, -R^e, -OR^c, -NR^cR^d, -NR^cS(O)₂R^e and -NR^dC(O)R^c; R^{3a} is selected from the group consisting of NH₂, CF₃, SCH₃ and Y; R^{3b} is chloro or bromo; and R^{3c} is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl.

41. (Previously Presented) A compound of claim **40**, wherein R¹, when present, is methyl, optionally substituted with a member selected from the group consisting of -OH, -OR^m, and -S(O)₂R^m.


42. (Previously Presented) A compound of claim **18**, having the formula:



wherein R^{2c} is halogen, cyano or nitro; R^{2b} is selected from -SR^c, -O-X²-OR^c, -X²-OR^c, -R^e, -OR^c, -NR^cR^d, -NR^cS(O)₂R^e and -NR^dC(O)R^c; R^{3a} is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl; R^{3c} is selected from the group consisting of NH₂, CF₃, SCH₃ and Y; and R^{3b} is chloro or bromo.

43. (Previously Presented) A compound of claim **42**, wherein R¹, when present, is methyl, optionally substituted with a member selected from the group consisting of -OH, -OR^m, and -S(O)₂R^m.


44. (Previously Presented) A compound of claim 18, having the formula:



wherein R^{2a} is other than hydrogen; R^{2c} is halogen, cyano or nitro; R^{2d} is selected from -SR^c, -O-X²-OR^c, -X²-OR^c, -R^e, -OR^c, -NR^cR^d, -NR^cS(O)₂R^e and -NR^dC(O)R^c; R^{3a} is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl; R^{3b} is chloro or bromo; and R^{3c} is selected from the group consisting of NH₂, CF₃, SCH₃ and Y.

45. (Previously Presented) A compound of claim 44, wherein R¹, when present, is methyl, optionally substituted with a member selected from the group consisting of -OH, -OR^m, and -S(O)₂R^m.

46. (Previously Presented) A compound of claim 18, having the formula:



wherein R^{2a} is other than hydrogen; R^{2c} is halogen, cyano or nitro; R^{2d} is -SR^c, -O-X²-OR^c, -X²-OR^c, -R^e, -OR^c, -NR^cR^d, -NR^cS(O)₂R^e and -NR^dC(O)R^c; R^{3a} is selected from the group consisting of NH₂, CF₃, SCH₃ and Y; R^{3b} is chloro or bromo; and R^{3c} is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₃₋₆ cycloalkyl.

47. (Previously Presented) A compound of claim 46, wherein R¹, when present, is methyl, optionally substituted with a member selected from the group consisting of -OH, -OR^m, and -S(O)₂R^m.

48. (Canceled)

49. (Canceled)

50. (Canceled)

51. (Canceled)

52. (Canceled)

53. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 1.